Compare MTH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTH | RLAY |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 1997 | 2020 |
| Metric | MTH | RLAY |
|---|---|---|
| Price | $71.68 | $19.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $77.63 | $19.50 |
| AVG Volume (30 Days) | 752.3K | ★ 2.0M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 2.18 | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.81 | $324.03 |
| P/E Ratio | $32.59 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $58.03 | $3.44 |
| 52 Week High | $85.38 | $21.27 |
| Indicator | MTH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 49.08 |
| Support Level | $68.50 | $18.02 |
| Resistance Level | $78.72 | $20.59 |
| Average True Range (ATR) | 2.05 | 0.90 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 28.65 | 26.78 |
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.